Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
作者机构：Department of Obstetrics and GynecologyTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China Cancer Biology Research Center(Key Laboratory of the Ministry of Education)Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China Department of HematologyTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2023年第8卷第9期
页 面：4188-4213页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：This study was supported by the National Natural Science Foundation of China(81974414 81772788 81873430)
主 题：clinical breakthrough dilemma
摘 要：Immune-checkpoint inhibitors(ICBs),in addition to targeting CTLA-4,PD-1,and PD-L1,novel targeting LAG-3 drugs have also been approved in clinical *** the widespread use of the drug,we must deeply analyze the dilemma of the agents and seek a breakthrough in the treatment *** the past decades,these agents have demonstrated dramatic efficacy,especially in patients with melanoma and non-small cell lung cancer(NSCLC).Nonetheless,in the field of a broad concept of solid tumours,non-specific indications,inseparable immune response and side effects,unconfirmed progressive disease,and complex regulatory networks of immune resistance are four barriers that limit its widespread ***,the successful clinical trials of novel ICB agents and combination therapies,the advent of the era of oncolytic virus gene editing,and the breakthrough of the technical barriers of mRNA vaccines and nano-delivery systems have made remarkable breakthroughs *** this review,we enumerate the mechanisms of each immune checkpoint targets,associations between ICB with tumour mutation burden,key immune regulatory or resistance signalling pathways,the specific clinical evidence of the efficacy of classical targets and new targets among different tumour types and put forward dialectical thoughts on drug ***,we discuss the importance of accurate triage of ICB based on recent advances in predictive biomarkers and diagnostic testing techniques.
维普期刊数据库